Eli Lilly Shares Rally 5% on Retatrutide’s 28.3% Weight Loss Data
LLY•Shares jumped nearly 5% pre-market after Phase 3 Triumph-1 data showed up to 28.3% weight loss at 80 weeks and up to 2-point A1C reduction. Oral Foundayo trials produced up to 14.4% weight loss in menopausal women, boosting projected 62% market share in a $150 B GLP-1 market by 2030.
1. Phase III Triumph-1 and Transcend-T2D-1 Results
Eli Lilly reported Phase 3 Triumph-1 data showing Retatrutide delivered an average 28.3% body weight reduction at 80 weeks in adults with obesity and up to a two-percentage-point decline in A1C among type 2 diabetes patients. The trial also noted improvements in knee osteoarthritis pain, sleep apnea symptoms, cholesterol levels and blood pressure, underscoring Retatrutide’s broad therapeutic potential.
2. Foundayo Menopause Trial Outcomes
Results from the Attain-1 and Attain-2 studies revealed that oral obesity drug Foundayo produced up to 14.4% weight loss in women across all stages of menopause after 72 weeks. The trials demonstrated consistent benefits in pre- and post-menopausal patients, including significant reductions in waist circumference and robust weight-loss milestones for those with type 2 diabetes.
3. Market Impact and Stock Performance
Shares of Eli Lilly surged nearly 5% in pre-market trading following the data presentations, pushing the stock toward record highs. With TD Cowen raising its GLP-1 market forecast to $150 billion by 2030 and projecting Lilly to capture about 62% of that market, the company’s GLP-1 portfolio continues to drive investor confidence.
